H.C. Wainwright raised the firm’s price target on Lexeo Therapeutics (LXEO) to $23 from $21 and keeps a Buy rating on the shares after alignment was reached the with FDA on a registrational path for LX2006.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics price target raised to $25 from $23 at Chardan
- Lexeo Therapeutics price target lowered to $19 from $20 at Leerink
- Lexeo Therapeutics Strengthens Leadership with New Board Appointment
- Lexeo Therapeutics reaches FDA alignment on development plan for LX2006
- Lexeo Therapeutics reports Q3 EPS (89c), consensus (68c)